Treatment and survival of de novo HER2-positive metastatic breast cancer across regional cancer networks in the Netherlands: a cohort study
Background Human epidermal growth factor receptor 2 (HER2)-targeted therapy has improved survival in HER2-positive metastatic breast cancer (MBC). Real-world practice may differ across oncologic networks, even within countries with uniform treatment guidelines. We assessed regional variation in first-line treatment and...